Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

GILEAD SCIENCES, INC.

(GILD)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies
Analyst Recommendations on GILEAD SCIENCES, INC.
10:26aGILEAD SCIENCES : UBS Adjusts Gilead Sciences' Price Target to $68 From $64, Mai..
MT
07/30GILEAD SCIENCES : SVB Leerink Adjusts Price Target on Gilead Sciences to $77 Fro..
MT
07/30GILEAD SCIENCES : BMO Capital Adjusts Gilead Sciences' Price Target to $72 From ..
MT
07/30GILEAD SCIENCES : RBC Boosts Price Target on Gilead Sciences to $84 From $81, Ma..
MT
07/30ANALYST RECOMMENDATIONS : Amazon, Barclays, Comcast, Next, Pfizer...
07/08GILEAD SCIENCES : RBC Capital Adjusts Gilead Sciences PT to $81 From $82 Expecti..
MT
04/30GILEAD SCIENCES : Morgan Stanley Adjusts Price Target on Gilead Sciences to $83 ..
MT
04/19GILEAD SCIENCES : Morgan Stanley Adjusts Price Target on Gilead Sciences to $81 ..
MT
04/19GILEAD SCIENCES : Credit Suisse Adjusts Gilead Sciences' Price Target to $69 fro..
MT
04/08GILEAD SCIENCES : RBC Capital Adjusts Price Target on Gilead Sciences to $82 Fro..
MT
04/01GILEAD SCIENCES : Bernstein Upgrades Gilead Sciences to Outperform Rating From M..
MT
03/30GILEAD SCIENCES : Redburn Upgrades Gilead Sciences to Buy From Neutral
MT
02/11GILEAD SCIENCES : SVB Leerink Adjusts Gilead Sciences' Price Target to $72 From ..
MT
02/05GILEAD SCIENCES : Credit Suisse Adjusts Gilead Sciences' Price Target to $66 fro..
MT
02/05GILEAD SCIENCES : Morgan Stanley Adjusts Price Target on Gilead Sciences to $87 ..
MT
01/19GILEAD SCIENCES : Morgan Stanley Upgrades Gilead Sciences to Overweight From Equ..
MT
2020GILEAD SCIENCES : Truist Adjusts Price Target on Gilead Sciences to $62 From $67..
MT
2020GILEAD SCIENCES : Oppenheimer Adjusts Gilead Sciences PT to $100 From $105, Main..
MT
2020GILEAD SCIENCES : BMO Capital Adjusts Gilead Sciences PT to $62 From $64, Mainta..
MT
2020GILEAD SCIENCES : Credit Suisse Adjusts Gilead Sciences' Price Target to $65 Fro..
MT
2020GILEAD SCIENCES : Redburn Reinstates Gilead Sciences at Neutral
MT
2020PFIZER, GILEAD, ROSS : What to Watch When the Stock Market Opens Today
DJ
2020Pfizer Says Covid Vaccine Is 95% Effective in Final Data, Will Seek Authoriza..
DJ
2020Pfizer's Covid-19 Vaccine 95% Effective in Final Results, Company to Seek App..
DJ
2020GILEAD SCIENCES : Morgan Stanley Reinstates Gilead Sciences at Equal-Weight With..
MT
2020GILEAD SCIENCES : remdesivir gets U.S. FDA approval for hospitalized COVID-19 pa..
RE
2020Hospitalized Covid-19 Patients Recovered Faster With Arthritis Drug
DJ
2020SPECIAL REPORT : Big Pharma wages stealth war on drug price watchdog
RE
2020U.S. Stock Futures Pause After S&P 500's Record Close
DJ
2020U.S. Stock Futures Edge Up After S&P 500's Record Close
DJ
2020U.S. Stock Futures Edge Up After S&P 500's Record Close
DJ
2020Hikma shares jump after improved sales outlook, COVID-19 drug deal
RE
2020Hikma shares jump after improved sales outlook, COVID-19 drug deal
RE
2020U.S. companies seeking capital during pandemic test bank market's new normal
RE
2020GILEAD SCIENCES : Covid-19 Drug Remdesivir to Cost $3,120 for Typical Patient --..
DJ
2020GILEAD SCIENCES : Covid-19 Drug Remdesivir to Cost $3,120 for Typical Patient --..
DJ
2020GILEAD SCIENCES : Covid-19 Drug Remdesivir to Cost $3,120 for Typical Patient --..
DJ
2020GILEAD SCIENCES : Covid-19 Drug Remdesivir to Cost $3,120 for Typical Patient --..
DJ
2020GILEAD SCIENCES : DZ Bank reaffirms its Buy rating
MD
2020GILEAD'S REMDESIVIR COULD SEE $7 BIL : analyst
RE
2020GSK's long-acting injection beats Truvada in HIV prevention trial
RE
2020Gilead disputes report that its drug flopped in leaked coronavirus trial
RE
2020Stock market gains alongside economic pain; some worry about over-optimism
RE
2020Report says COVID-19 patients respond to Gilead's remdesivir, shares surge
RE
2020Drugmakers see long road ahead in coronavirus vaccine race
RE
2019Gilead invests $5 billion to deepen ties with biotech Galapagos
RE
2019Gilead invests $5 billion to deepen ties with biotech Galapagos
RE
2018Galapagos, Gilead bask in $4-6 billion new drug sales hope
RE
2018GlaxoSmithKline prescribes commercial reboot for pharma division
RE
2018GlaxoSmithKline prescribes commercial reboot for pharma division
RE
2018FTSE slides after BOE meeting as pound pops higher
RE
2017Gilead and GSK go head-to-head with similar HIV drug data
RE
2017Gilead challenges GSK with strong HIV drug data
RE
2015ABBVIE : revenue miss raises concerns over Humira sales
RE
2015Wall St. ends lower with oil prices, renewed Greece worries
RE
2014Irish tax changes may cost U.S. groups billions
RE
2013Fast-growing Humira extends domination of AbbVie
RE
2013Europe backs new dual-action Novartis lung drug
RE
2013Factbox - U.S. biotech shares outpace broader stock market
RE
2009GILEAD SCIENCES : Gilead profit rises a higher-than-expected 21 percent
RE
Official Publications
06/15Report 
06/10Report 
05/12Report 
05/12SEC Filing 8K 
05/06SEC Filing 10Q-1 
05/06Report 
Upcoming event on GILEAD SCIENCES, INC.